The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
New research reveals GLP-1 medications like Ozempic may significantly elevate risks of bone disorders and tendon injuries. Analyzing nearly 150,000 patients, the study found 30% higher osteoporosis rates and 50% increased tendon rupture risks over five years. Experts urge bone density monitoring amid these findings.
A groundbreaking study in the British Medical Journal reveals that GLP-1 drugs like Ozempic offer benefits far beyond weight loss and diabetes control—they significantly reduce risks of alcohol, tobacco, cannabis, and cocaine abuse. Among 606,434 US veterans with type 2 diabetes, these medications lowered substance abuse risks by up to 20%. Experts caution that while promising, more research is needed.
Jessica Simpson, the 45-year-old star who rose to fame at 19 with 'I Wanna Love You Forever,' has fans buzzing over her transformed appearance. Speculation points to 'Ozempic face'—sunken eyes, sagging skin from GLP-1 drugs—but Simpson insists it's all willpower and healthy habits after losing 100 pounds post-pregnancy.
Meghan Trainor's striking transformation, showcased in side-by-side photos from 2014 and 2025, has ignited debates on 'Ozempic face' from GLP-1 drugs like Mounjaro. While her defined jawline looks stunning, experts note rapid fat loss can accelerate aging signs like sunken cheeks and wrinkles. Learn the facts amid body positivity backlash.
The months-long GLP-1 feud between Novo Nordisk and Hims & Hers Health is over, with a new partnership to sell Wegovy via Hims' telehealth platform expected Monday. Following a recent lawsuit over copycat drugs, shares surged: Hims nearly 40%, Novo 2% after-hours. Analysts call it a surprise positive for expanded market reach.
Patients on GLP-1 drugs like Ozempic report losing interest in cigarettes, alcohol, and more without effort. A physician-led study of over 600,000 VA patients reveals these medications cut addiction-related deaths by 50% and prevent new substance use disorders. This could transform treatment for alcohol, opioids, cocaine, cannabis, and nicotine.
A spectacular backfire in Novo Nordisk's head-to-head trial against Eli Lilly's Mounjaro has widened the gap in the weight loss drug race, yet Ireland stands to gain from both giants. With billions in investments, thousands of jobs, and massive tax revenues, the Republic is placing an each-way bet on Wegovy and Mounjaro. This economic tie underscores pharma's pivotal role in Ireland's prosperity.
A new analysis shows semaglutide, the key ingredient in Ozempic and Wegovy, can be produced for just $3 per month. As patents expire in countries like Brazil, China, and India, generics could dramatically boost access to obesity and diabetes treatments worldwide. This development offers hope amid rising global rates of these conditions.
As GLP-1 drugs like Ozempic revolutionize obesity and diabetes care, muscle weakness emerges as a key challenge. Dr. Bob reveals why 47-65% discontinue treatment, patient perceptions vs. reality, and proven strategies like protein intake and strength training. Explore the next frontier in preserving muscle for long-term health.
